Therapeutic Nanomedicine

Therapeutic Nanomedicine includes the planning, production, characterization and testing of nanocarriers able to couple technological properties of pharmaceutical nanoformulation (drug loading, protection against metabolism and elimination, controlled or triggered drug release) together with unique properties of advanced strategies as selective drug targeting against specific organs, areas or even pathological cell population.
Drug delivery and drug targeting is therefore representing a new era of strategic approaches for curing pathologies as cancer, brain diseases, infections or rare disorders, which are, up to today, difficult to treat or even without a real option for life.
UniMORE displays a number of laboratories actively working in each section of the workflow of Therapeutic Nanomedicine field, from the planning up to formulation and testing.

Main fields

1. Design and modelling

  • Data Mining/Experimental Design on self-assembly nanoproducts
  • Computational approach for targets identification
  • Modelling and design of nanomedicine surface engineering and interaction with proteins
  • Software and methods for multiscale simulations and analysis of complex molecular systems
  • Statistical modelling and simulation for synaptic transmission

2. Bioconjugates

  • Preclinical drug discovery
  • Bioconjugates
  • Protein chemistry
  • Prodrugs
  • Synthesis and functionalization of complex and small molecules

3. Production & Characterization of drug delivery systems (DDS)

  • Design, formulation, production of polymeric DDS for active drug delivery and targeting
  • Design, formulation, production of engineered non-viral DDS
  • Design, formulation, production of novel solid lipid DDS
  • Design and production of DDS with antimicrobial activity
  • Design and production of inorganic DDS
  • Advanced nanodelivery
  • Full chemico-physical and morphological characterization of nanomedicines

4. Targets and Pathologies

  • Brain disorders (AD, PD, HD)
  • Rare Disease (LSD, Genetic disorder)
  • Cancer
  • Gene Therapy
  • Alveolar/Lung
  • Parasitic Infectious & Prevention

5. Testing in vitro

  • Oncology (Lymphoma, PEL, colo-rectal cancer)
  • Central Nervous System (neurons, astrocyte, etcc.)
  • In vitro models for neurodegenerative disorders (i.e. AD) or motor disorders (ALS)
  • Hepato and Brain cancer cell lines or models

6. Testing in vivo

  • CNS pathology (AD)
  • CNS (electrophysiology, spinal cord)
  • Oncology
  • Infectious disease animal model.